Sanchez-Patan Fernando, Anchuelo Raquel, Vara Elena, Garcia Cruz, Saavedra Yolanoa, Vergara Patri, Cuellar Carmen, Rodero Marta, Aller Maria-Angeles, Arias Jaime
Department of Surgery I, School of Medicine, Complutense University of Madrid, Spain.
Hepatobiliary Pancreat Dis Int. 2008 Aug;7(4):383-94.
Since we have previously shown an increase of mast cells in the small bowel and in the mesenteric lymph nodes in the rats with prehepatic portal hypertension, it can be hypothesized that this essential inflammatory cell would be involved in the pathogeny of the splanchnic changes related to portal hypertension.
To verify this hypothesis, we first studied mast cell infiltration in the ileum and in the mesenteric lymph nodes in sham-operated male Wistar rats (n=12) and in short-term prehepatic portal hypertensive rats (n=12), and the serum levels of rat mast cell protease II (RMCP-II) by ELISA. In a second set of experiments ketotifen, a mast cell stabilizer drug, was administered to sham-operated (n=10) and portal hypertensive (n=12) rats 24 hours before the intervention and prostanoids (PGE2, PGI2, TXB2) and leukotrienes (LTC4, LTB4) were assayed by RIA, mast cell infiltration in the ileum and in the mesenteric lymph nodes and the serum levels of RMCP-II were also studied, to show its effectiveness to prevent the mesenteric alterations produced by the inflammatory mediators released by the mast cell.
Forty-eight hours after the intervention RMCP-II (P<0.05), PGE2 (P<0.001) and LTC4 serum levels decreased and mast cell number and RMCP-II levels increased in mesenteric lymph nodes in portal hypertensive rats. Prophylactic administration of ketotifen reduced portal pressure (P<0.001), serum levels of PGE2 (P<0.001) and RMCP-II (P<0.001) in mesenteric lymph nodes.
In acute portal hypertension in the rat, the mast cell translocation from intestinal mucosa to mesenteric lymph nodes, where they are activated and degranulates, would represent a defence mechanism to avoid the activation of an acute and massive inflammatory response in this location. Prophylactic administration of ketotifen is able to reduce the splanchnic inflammatory changes related to acute portal hypertension in the rat.
由于我们之前已表明,肝前性门静脉高压大鼠的小肠和肠系膜淋巴结中肥大细胞数量增加,因此可以推测,这种重要的炎症细胞会参与门静脉高压相关内脏改变的发病机制。
为验证这一假设,我们首先研究了假手术雄性Wistar大鼠(n = 12)和短期肝前性门静脉高压大鼠(n = 12)的回肠和肠系膜淋巴结中的肥大细胞浸润情况,并通过酶联免疫吸附测定法检测大鼠肥大细胞蛋白酶II(RMCP-II)的血清水平。在第二组实验中,在干预前24小时给假手术大鼠(n = 10)和门静脉高压大鼠(n = 12)施用肥大细胞稳定剂酮替芬,通过放射免疫分析法检测前列腺素(PGE2、PGI2、TXB2)和白三烯(LTC4、LTB4),同时研究回肠和肠系膜淋巴结中的肥大细胞浸润情况以及RMCP-II的血清水平,以显示其预防肥大细胞释放的炎症介质引起的肠系膜改变的有效性。
干预48小时后,门静脉高压大鼠的RMCP-II(P < 0.05)、PGE2(P < 0.001)和LTC4血清水平降低,肠系膜淋巴结中的肥大细胞数量和RMCP-II水平增加。预防性施用酮替芬可降低门静脉压力(P < 0.001)、肠系膜淋巴结中PGE2(P < 0.001)和RMCP-II(P < 0.001)的血清水平。
在大鼠急性门静脉高压中,肥大细胞从肠黏膜转移至肠系膜淋巴结并在那里被激活和脱颗粒,这可能是一种防御机制,以避免该部位发生急性和大规模炎症反应。预防性施用酮替芬能够减轻大鼠急性门静脉高压相关的内脏炎症变化。